HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS

Mazyar Shadman, Joachim Deeg
  • Mazyar Shadman
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA, USA, United States | mshadman@fhcrc.org
  • Joachim Deeg
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA, USA, United States

Abstract

The incidence of myeloid malignancies, including myelodysplastic syndromes (MDS) increases with age. While several therapeutic modalities have been developed, for most of these patients the only treatment with curative potential is allogeneic hematopoietic cell transplantation (HCT). The development of reduced/low intensity transplant conditioning regimens allows to successfully transplant patients in their ‘60s and even ‘70s, although comorbidities may determine who does come to transplantation and who does not. Also, as many as half of the patients will develop graft versus host disease (GVHD), even with HLA matched  donors, requiring therapy for extended periods of time,  and GVHD and treatment  with glucocorticoids is likely to impact the quality  of life. Nevertheless, dependent upon disease stage at HCT, the presence of comorbidities and the regimen used, 30% to 50% of patients  60 years of age or older, may survive long-term cured of their disease. Future studies should focus on the incorporation of non-transplant modalities into the overall transplant approach, the prevention of GVHD, and the utilization of immunotherapy to reduce the incidence of relapse and GVHD and further improve overall transplant success.

Keywords

MDS;Transplantation;Elderly

Full Text:

PDF
HTML
Submitted: 2014-08-29 14:02:26
Published: 2014-09-01 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
263

Views:
PDF
132
HTML
2187

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185